SCHEMBL11238732

SCHEMBL11238732

CC(C)OC(=O)C1C2CCC(C2)C1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 4/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.38
CHRNA1 P02708 1/20 0.38
CHRNG P07510 1/20 0.38
ITGA5 P08648 1/20 0.38
CHRNB1 P11230 1/20 0.38
CHRNB2 P17787 1/20 0.38
SLC6A2 P23975 1/20 0.38
CHRNB4 P30926 1/20 0.38
SLC6A4 P31645 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CHRND Q07001 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13518554 0.92 CHRNA1 (0.41) CHRNA1CHRNGITGA5CHRNB1CHRNB2
SCHEMBL12019108 0.83 NPC1 (0.38) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL14874658 0.83 TSHR (0.43) CHRNA1CHRNGITGA5CHRNB1CHRNB2
SCHEMBL14874659 0.83 TSHR (0.43) CHRNA1CHRNGITGA5CHRNB1CHRNB2
SCHEMBL29259887 0.81 TSHR (0.42) CHRNA1CHRNGITGA5CHRNB1CHRNB2
SCHEMBL15647517 0.80 PPM1B (0.35) ALDH1A1HTTLMNACHRNA1CHRNG
SCHEMBL23698034 0.80 LMNA (0.52) NPC1RAB9AALDH1A1KMT2ALMNA
SCHEMBL14433686 0.80 LMNA (0.52) NPC1RAB9AALDH1A1KMT2ALMNA
SCHEMBL1004125 0.80 LMNA (0.52) NPC1RAB9AALDH1A1KMT2ALMNA
SCHEMBL3045980 0.80 LMNA (0.52) NPC1RAB9AALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182606-A1 METHOD FOR PRODUCING PROPYLENE COPOLYMER USING CATALYST SYSTEM HAVING IMPROVED COPOLYMERIZATION ACTIVITY HANWHA TOTALENERGIES PETROCHEMICAL CO., LTD. (KR) 2024-06-06 US disclosed
EP-4375303-A1 METHOD FOR PRODUCING PROPYLENE COPOLYMER USING CATALYST SYSTEM HAVING IMPROVED COPOLYMERIZATION ACTIVITY Hanwha TotalEnergies Petrochemical Co., Ltd. (KR) 2024-05-29 EP disclosed
EP-4361186-A1 SOLID CATALYST FOR PRODUCING POLYPROPYLENE AND METHOD FOR PREPARATION OF PROPYLENE-DERIVED POLYMER Hanwha TotalEnergies Petrochemical Co., Ltd. (KR) 2024-05-01 EP disclosed
US-10308563-B2 Process for producing ethylene oligomers HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) 2019-06-04 US disclosed
US-20180170827-A1 PROCESS FOR PRODUCING ETHYLENE OLIGOMERS HANWHA TOTALENERGIES PETROCHEMICAL CO., LTD. (KR) 2018-06-21 US disclosed
US-20180169642-A1 CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) 2018-06-21 US disclosed
US-20140005345-A1 SOLID CATALYST FOR PROPYLENE POLYMERIZATION AND A METHOD FOR PREPARATION OF POLYPROPYLENE HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) 2014-01-02 US disclosed
US-8394734-B2 Solid catalyst for propylene polymerization and a method for preparation of polypropylene using the same SAMSUNG TOTAL PETROCHEMICALS CO., LTD. (KR) 2013-03-12 US disclosed
US-20120277389-A1 SOLID CATALYST FOR PROPYLENE POLYMERIZATION AND A METHOD FOR PREPARATION OF POLYPROPYLENE USING THE SAME SAMSUNG TOTAL PETROCHEMICALS CO., LTD. (KR) 2012-11-01 US disclosed
US-4349552-A TREATMENT OF CANCER FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1982-09-14 US disclosed
EP-0010941-B1 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-05-12 EP disclosed
EP-0010941-A1 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308563-B2 Process for producing ethylene oligomers OXER1, HAO2, ORC3 NPC1 1536/4885RAB9A 3258/4885ALDH1A1 1507/4885
US-20180169642-A1 CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME HACL2, HAO2, MSMO1 NPC1 1894/4885RAB9A 3554/4885ALDH1A1 1614/4885
US-20180170827-A1 PROCESS FOR PRODUCING ETHYLENE OLIGOMERS OXER1, HAO2, ORC3 NPC1 1536/4885RAB9A 3258/4885ALDH1A1 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.